SCHEMBL8205751

SCHEMBL8205751

CC(C)NC(=O)c1cccc(C(=O)NCc2ccc(Cl)nc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
HTT P42858 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
HPGD P15428 3/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP2C9 P11712 2/20 0.42
NAMPT P43490 1/20 0.42
FAAH O00519 1/20 0.42
LMNA P02545 1/20 0.41
KLKB1 P03952 1/20 0.41
KLK1 P06870 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HDAC1 Q13547 1/20 0.41
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8212490 0.86 CA1 (0.46) HTTCA1CA2HPGDALDH1A1
SCHEMBL8198502 0.85 SMN1; SMN2 (0.53) HTTCA1CA2HPGDALDH1A1
SCHEMBL8205711 0.85 SMN1; SMN2 (0.44) HPGDALDH1A1CYP2C9LMNAKDM4E
SCHEMBL8212427 0.84 SMN1; SMN2 (0.41) HTTCNR1MEN1KMT2AMAPK8
SCHEMBL8209069 0.83 CNR2 (0.47) CNR1MEN1KMT2A
SCHEMBL29333050 0.81 SMN1; SMN2 (0.51) L3MBTL1CA1CA2HPGDALDH1A1
SCHEMBL8198357 0.81 CNR1 (0.52) L3MBTL1HPGDALDH1A1LMNAHDAC1
SCHEMBL8199936 0.81 CACNA1G (0.52) HPGDALDH1A1LMNAKLKB1KLK1
SCHEMBL8205735 0.81 HTT (0.61) HTTHPGDALDH1A1LMNAGAA
SCHEMBL8205783 0.81 MEN1 (0.52) HPGDALDH1A1LMNAKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 L3MBTL1 2541/4885HTT 4776/4885CA1 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.